Head-To-Head Contrast: Verrica Pharmaceuticals (NASDAQ:VRCA) versus United Therapeutics (NASDAQ:UTHR)

Verrica Pharmaceuticals (NASDAQ:VRCA) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Risk and Volatility

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Profitability

This table compares Verrica Pharmaceuticals and United Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
United Therapeutics	40.62%	19.24%	17.25%

Insider and Institutional Ownership

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Verrica Pharmaceuticals and United Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1	1	2	0	2.25
United Therapeutics	0	2	11	0	2.85

Verrica Pharmaceuticals presently has a consensus price target of $14.50, indicating a potential upside of 150.43%. United Therapeutics has a consensus price target of $619.42, indicating a potential upside of 14.70%. Given Verrica Pharmaceuticals’ higher probable upside, research analysts clearly believe Verrica Pharmaceuticals is more favorable than United Therapeutics.

Earnings & Valuation

This table compares Verrica Pharmaceuticals and United Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58 million	2.80	-$17.89 million	($1.03)	-5.62
United Therapeutics	$3.18 billion	7.20	$1.33 billion	$27.09	19.94

United Therapeutics has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

United Therapeutics beats Verrica Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.